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Background: Low endogenous testosterone levels have been shown to be a risk factor for the development of
cardiovascular disease and cardiovascular benefits associated with testosterone replacement therapy are being
advocated; however, the effects of endogenous testosterone levels on acute coronary vasomotor responses to
androgen administration are not clear. The objective of this study was to compare the effects of acute androgen
administration on in vivo coronary conductance and in vitro coronary microvascular diameter in intact and
castrated male swine.
Methods: Pigs received intracoronary infusions of physiologic levels (1–100 nM) of testosterone, the metabolite
5α-dihydrotestosterone, and the epimer epitestosterone while left anterior descending coronary blood flow and
mean arterial pressure were continuously monitored. Following sacrifice, coronary arterioles were isolated,
cannulated, and exposed to physiologic concentrations (1–100 nM) of testosterone, 5α-dihydrotestosterone, and
epitestosterone. To evaluate effects of the androgen receptor on acute androgen dilation responses, real-time
PCR and immunohistochemistry for androgen receptor were performed on conduit and resistance coronary vessels.
Results: In vivo, testosterone and 5α-dihydrotestosterone produced greater increases in coronary conductance in the
intact compared to the castrated males. In vitro, percent maximal dilation of microvessels was similar between intact
and castrated males for testosterone and 5α-dihydrotestosterone. In both studies epitestosterone produced significant
increases in conductance and microvessel diameter from baseline in the intact males. Androgen receptor mRNA
expression and immunohistochemical staining were similar in intact and castrated males.
Conclusions: Acute coronary vascular responses to exogenous androgen administration are increased by endogenous
testosterone, an effect unrelated to changes in androgen receptor expression.
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Cardiovascular disease is a leading cause of morbidity and
mortality worldwide. For years the high incidence of car-
diovascular disease in males was hypothesized to be
related to the detrimental effects of testosterone on the
vasculature. However, recent studies have demonstrated
low testosterone levels are associated with a number of
cardiovascular risk factors including obesity, hypertension,* Correspondence: bowlesd@missouri.edu
1Department of Biomedical Sciences, University of Missouri, Columbia, MO
65211, USA
2Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO
65211, USA
© 2012 O'Connor et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhypercholesterolemia, and hypertriglyceridemia [1,2]. Low
endogenous testosterone levels have been linked to
reduced exercise capacity in men with heart failure [3], ca-
rotid atherosclerosis [4], impaired vascular reactivity [5]
and increased severity of coronary artery disease [6]. A
similar relationship between endogenous androgen levels
and cardiovascular disease has also been demonstrated in
animal models. Ten weeks following the castration of
male Sprague Dawley rats, aortic endothelial damage was
detectable by electron microscopy that was absent in the
intact males. Similar ultrastructural changes were noted
in intact males treated with a 5α –reductase inhibitor [7].
Previous work from our lab demonstrated that in a swine
model of post-angioplasty restenosis, neointima formationral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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males compared to both intact males and hormone
replaced castrated males [8].
As a result of these studies, androgen therapy in hypo-
gonadal men for the purpose of cardioprotection is a con-
cept that has gained popularity in recent years. Human
studies have shown that men with coronary heart disease
show improved myocardial perfusion and reduced arterial
stiffness following chronic oral testosterone therapy [9].
Similarly, transdermal testosterone therapy reduced arter-
ial stiffness in elderly hypogonadal men [10]. In a rabbit
model of atherosclerosis, castrated male rabbits on a high
cholesterol diet that received subcutaneous dihydrotestos-
terone supplementation demonstrated reduced aortic
plaque area compared to the placebo group [11]. Acutely,
testosterone and the non-aromatizable metabolite di-
hydrotestosterone have been identified as dilators of blood
vessels in both human and animal studies. High dose
intravenous testosterone increased flow mediated dilation
in men with coronary artery disease [12]. Similarly, acute
intracoronary administration of physiologic doses of tes-
tosterone increased vessel diameter and blood flow of the
coronary vessels in men with coronary artery disease [13].
Various animal models using rodents, rabbits, dogs, and
swine have also demonstrated an acute dilation to andro-
gen in both in vivo and in vitro studies [14-18]. However,
while the acute and chronic effects of exogenous androgen
have been evaluated, it is unknown what role endogenous
testosterone levels have on these vascular responses in
humans or animals.
Previous studies on the cardiovascular effects of andro-
gen have focused largely on the effects of testosterone and
its non-aromatizable metabolites 5α and 5β-dihydrotestos-
terone, but to date the vascular responses of the epimer
epitestosterone have not been evaluated. Epitestosterone is
a naturally occurring androgen produced by the testis and
adrenal gland in humans. It is structurally similar to tes-
tosterone but in humans it has not been shown to be a
testosterone derivative [19]. Because of the constant ratio
of testosterone to epitestosterone in the circulation, the
majority of research on epitestosterone is related to its
use as a marker of blood doping in athletes [20]. Several
studies have also described epitestosterone as having
weak anti-androgen effects based on its ability to inhibit
testosterone conversion to dihydrotestosterone [21]. The
majority of the current literature on epitestosterone indi-
cates that it lacks any significant biologic activity [19],
though several sources suggest it may contribute to
the regulation of androgen dependent events [20,21].
Because of the structural similarity to testosterone and
affinity for the androgen receptor, we hypothesized
that epitestosterone would demonstrate similar vaso-
motor responses to testosterone and 5α-dihydrotestoster-
one when administered acutely.Testosterone has been described as both a calcium
channel antagonist [16,22–24] and potassium channel
agonist [14,15,18]. More recently the androgen receptor
has been identified as a possible key factor in the mechan-
isms of androgen induced vascular responses. Androgen’s
stimulatory effects on angiogenesis [25] and inhibitory
effects on plaque development in atherosclerosis [11,26]
have been shown to be mediated at least in part to andro-
gen signaling through the androgen receptor. In coronary
arteries from 24 men, there was a negative correlation
between androgen receptor mRNA expression in the
media and plaque area [27]. Recently testosterone has
been shown to upregulate the phosphorylation of eNOS
and production of nitric oxide through activation of the
androgen receptor in human aortic endothelial cells, pro-
viding a potential mechanism for the acute androgen
induced vascular dilation demonstrated both in vitro and
in vivo [28]. Given the association of the androgen recep-
tor with the production of a critical mediator of vascular
tone suggests that endogenous testosterone levels and
subsequently, androgen receptor expression, may affect
the acute dilation responses to exogenous androgen ad-
ministration. If confirmed, the results could have import-
ant clinical implications for chronic therapy targeted at
improving the vascular health of hypogonadal men. We
therefore sought to evaluate the effects of endogenous an-
drogen on the acute vasomotor responses to exogenous
androgen administration in intact and castrated swine.
Methods
Animals
Male intact and castrated swine, ages ranging from 3 months
to 5.5 years (intacts 20.83±4.79 months; castrates
3.80±0.39 months) and weights ranging from 25–100 kg
(intacts 69.76±5.89 kg; castrates 31.20±1.59 kg) were
obtained for use in these studies. Domestic swine from the
University of Missouri were used for the majority of the
studies (Columbia, MO, USA). Minnesota Mini
(NSRRC:0005) and Yucatan (NSRRC:0012) males were
obtained from the National Swine Resource and Research
Center (www.nsrrc.missouri.edu) (Columbia, MO, USA).
Additional Yucatans were obtained from Sinclair Research
Farm (Columbia, MO, USA). All swine were housed at the
University of Missouri research animal facilities and fed a
standard pig chow (Purina Lab Mini-pig Breeder Diet
5082 or Purina Lab Mini-pig Grower Diet 5L80). Animal
protocols were approved by the University of Missouri
Animal Care and Use Committee in accordance with
the Guide for the Care and Use of Laboratory Animals
(National Academy Press, Washington, D.C., 1996).
Flow studies
Pigs were sedated with a combination of Telazol (5 mg/kg)
and xylazine (2.25 mg/kg) and maintained under isoflurane
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the 3rd-4th intercostal space to gain access to the left
anterior descending coronary artery (LAD). Following
blunt dissection, a transonic perivascular flow probe
(Transonic Systems Inc., Ithaca, NY, USA) was posi-
tioned at the proximal aspect of the LAD. A 6F guide
catheter (Boston Scientific, Quincy, MA, USA) was
then introduced through a 7F sheath placed in the right
femoral artery and positioned at the left main coronary
artery. An infusion catheter (Spectranetics, Colorado
Springs, CO, USA) was passed through the guide cath-
eter and positioned in the LAD just distal to the position
of the flow probe. Placement of the flow probe and infu-
sion catheter was confirmed using angiography.
In a subset of animals, a chronic intravascular LAD
catheter was inserted in place of the femoral artery infu-
sion catheter. An intravascular polyethylene aortic cath-
eter was also placed to allow for pressure measurements.
The perivascular flow probe was positioned as previously
described. The catheters and flow probe were exterior-
ized through the intercostal spaces and tunneled sub-
cutaneously to the dorsal cervical region. Pigs were
recovered and flow studies performed in the conscious
animals several days following surgery.
In both the anesthetized and conscious animals,
androgens were infused into the LAD for 5 minute
intervals. The androgens evaluated were testosterone,
5α-dihydrotestosterone, and epitestosterone (Sigma, St.
Louis, MO, USA). 50 μM (14 μg/mL), 500 μM (140 μg/mL),
and 5 mM (1400 μg/mL) solutions of androgen in 100%
ethanol were diluted in saline to make 50, 500, and
5,000 nM stocks of androgen. The order of the andro-
gens was randomly selected for each animal. Depending
on the animal’s baseline coronary blood flow, the rate of
infusion was altered to achieve final coronary androgen
concentrations of 1, 10, and 100 nM during the 5 mi-
nute infusions. At the beginning of the study a vehicle
control of 0.1% Ethanol was infused for 5 minutes. An
adenosine bolus (5ug/kg) was also administered prior to
androgen infusion to achieve maximal dilation of the cor-
onary vessels. In between androgens, saline boluses were
administered to wash out all remaining androgen and the
animal’s coronary blood flow was allowed to stabilize prior
to administration of the next androgen.
In a separate group of anesthetized intact animals,
androgens were infused individually and in the presence
of flutamide, an androgen receptor blocker. In these
experiments, the 500 nM doses of 5α-dihydrotestosterone
and epitestosterone were administered over 5 minutes
with saline flushes in between each androgen. Subse-
quently, a 10 mM (2.76 mg/mL) solution of flutamide in
100% ethanol was diluted in saline to make a 500 μM so-
lution and infused over 5 minutes at a rate to achieve cor-
onary concentrations of 10 μM flutamide. Following theflutamide infusion, the 500 nM androgens and the
500 μM flutamide were infused simultaneously over 5 mi-
nute intervals, with saline flushes in between androgens.
At the beginning of the study a vehicle control of 5% etha-
nol was infused for 5 minutes to account for the ethanol
concentration in the flutamide stock.
Flow study data was collected using a Transonic flow
meter (Transonic Systems Inc., Ithaca, NY, USA) and
Chart 5 PowerLab Software (ADInstruments, Colorado
Springs, CO, USA). Coronary blood flow and mean
arterial pressure were measured continuously during the
infusions. Upon completion of the flow study, the heart
was removed from the anesthetized animal for subse-
quent in vitro studies.
Microvessel studies
An ~3 cm diameter section of myocardium at the apex
of the left ventricle was harvested from explanted hearts
for microvessel studies. Vessels 100–300 μM in diameter
were dissected from the harvested section of left ven-
tricle. Vessels were then cannulated with glass micropip-
ettes and pressurized to 60 cm H2O in physiologic salt
solution (PSS) with albumin (NaCl 145 mM, KCl
4.7 mM, CaCl2H20 2.0 mM, MgSo47 H20 1.17 mM,
MOPS 3 mM, NaH2P04 1.2 mM, glucose 5 mM, pyru-
vate 2 mM, EDTA 0.02 mM, albumin 10 g, pH 7.4). Ves-
sels were maintained at 37°C and washed 3–4 times with
PSS at 15 minute intervals during an initial equilibration
period. Vessels that did not achieve a basal tone of at
least 20-40% during the equilibration period were pre-
constricted with endothelin-1 (3 pM-10 nM). Vessels
preconstricted with endothelin-1 were washed 2–3 times
prior to androgen administration. Increasing concentra-
tions of androgen were cumulatively administered dir-
ectly into the bath for 5 minute intervals. The androgens
evaluated were testosterone, 5α-dihydrotestosterone, and
epitestosterone (Sigma, St. Louis, MO, USA). 10 mM
(2800 μg/mL) stocks of androgen dissolved in 100%
ethanol were diluted in PSS buffer to make 0.1 μM,
1.0 μM and 10 μM solutions of androgen. Final concen-
trations of androgen achieved in the bath were 1, 10 and
100 nM. The order of the androgens was randomly
selected for each animal. Vessels were washed 2 times
with PSS at 15 minute intervals in between androgens. If
vessels did not achieve at least 20% tone following the
washout period, endothelin-1 was administered as previ-
ously described. Following the androgen dose response
experiments, the integrity of the endothelium was con-
firmed with 0.01 μM bradykinin in the bath. The experi-
ments were terminated with a final wash of the vessel
with a Ca free solution (NaCl 147 mM, KCl 4.7 mM,
MgSo47 H20 1.17 mM). Changes in microvessel diam-
eter were recorded using Chart 5 PowerLab Software
(ADInstruments, Colorado Springs, CO, USA).
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Quantitative RT- PCR (qRT-PCR) was performed to
amplify the androgen receptor and the constitutively
expressed gene, glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) as previously described with modifica-
tions [29,30]. LAD segments (10-mm axial length) and
microvessels were quick-frozen in liquid nitrogen and
stored at −80°C until processed. Frozen LAD segments
were pulverized under liquid nitrogen, and total RNA
was extracted (TRI Reagent, Molecular Research Center,
Cincinnati, OH). RNA was extracted from microvessels
using the PicoPure RNA Isolation kit (MDS Analytical
Technologies, Sunnyville, CA). cDNA was transcribed
from total RNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA)
using 50 units of Multiscribe Reverse Transcriptase in
a 20-μl reaction containing 50 μM random primers,
20 units of RNase Inhibitor, 100 mM dNTPs, and RT
Buffer. Quantitative RT-PCR was performed on a MyiQ
Single Color Real-Time PCR cycler (Bio-Rad, Hercules,
CA). Each 25-μl reaction contained iQ SYBR Green
Supermix (Bio-Rad, 170–8882), 0.8 μM forward and re-
verse primers, and 100 ng of cDNA. Each primer set
was optimized for cycle time and annealing temperature.
The PCR reactions were initiated by a 3 min incubation
at 95°C followed by 50 cycles of 95°C (60 sec), 58°C
(60 sec), and 72°C (60 sec) for androgen receptor.
GAPDH was amplified using 40 cycles of 95°C (15 sec),
58°C (30 sec), and 72°C (30 sec). Primers were designed
on the basis of published sequences from domestic
porcine (Sus scrofa). The primer sets were as follows:
androgen receptor: sense, 5’-GTC CCG AAT GTA CAG
CCA GT-3’; antisense, 5’-CTT GAG CAG GAT GTG
GGA TT-3’; GAPDH: sense, 5’-TCA AGA AGG TGG TGA
AGC AG-3’; antisense, 5’-TGT CGT ACG AGG AAA
TGA GC-3’. Target gene expression was normalized to
GAPDH ribosomal RNA using the 2 -ΔΔCt method [31].
Linearity and efficiency of each PCR condition were
verified by creating a standard curve plotting the critical
threshold vs. log of the dilution of cDNA.
Immunohistochemistry
Androgen receptor protein expression was evaluated in
the intact and castrated males using immunohistochem-
istry with a rabbit polyclonal antibody directed against
the androgen receptor as described previously [8,32].
Sections were incubated with avidin–biotin two-step
blocking solution (Vector SP-2001) to inhibit back-
ground staining and in 3% hydrogen peroxide to inhibit
endogenous peroxidase. Non-serum protein block (Dako
X909) was applied to inhibit non-specific protein bind-
ing. Primary antibody for androgen receptor (1:200,
PA1-110, Thermo Scientific) was incubated overnight
at 4°C. After appropriate washing steps, sections wereincubated with biotinylated secondary antibody in phos-
phate-buffered saline containing 15 mM sodium azide
and peroxidase-labeled streptavidin (Dako LSAB+ kit,
peroxidase, K0690). Diaminobenzidine (DAB, Dako) was
applied for 5 minutes to visualization of the reaction
product. Sections were photographed with an Olympus
BX40 photomicroscope and Spot Insight Colour camera
(Diagnostic Instruments). One section of left anterior
descending coronary artery and 2–3 microvessels for
each animal were analyzed. Digital color (RGB) images
were obtained. Quantification of the density of positive
staining for androgen receptor in the intima and media
was performed for each vessel utilizing ImagePro Plus
(Media Cybernetics). Briefly, pixels within the region of
interest identified as positive based on color selection
were analyzed for mean pixel density and percent of area
positive (area positive/total area).
Statistical analysis
In vivo data is expressed as percent change in coronary
conductance during each 5 minute infusion. Conduct-
ance was calculated from coronary blood flow and mean
arterial pressure measurements taken at 2 second inter-
vals during the flow studies. The baseline conductance
used for analysis was the mean conductance over a
30 second period immediately prior to each infusion.
The conductance for each infusion was the maximal
mean conductance over a 30 second period during the
5 minute infusion. Due to a transient vehicle induced
dilation observed at the beginning of the infusions, the
first 80 seconds of each infusion was excluded from ana-
lysis. Microvessel data is expressed as percent maximal
dilation. The maximal dilation of the coronary arteriole
was the maximum diameter of the vessel achieved dur-
ing the experiment. Percent maximal dilation was calcu-
lated using [(Da- Db)/(Dmax-Db) x 100], where Da is
diameter after androgen, Db is baseline diameter, and
Dmax is maximal diameter. Vessels that demonstrated
less than 20% tone following endothelin-1 or less than
40% maximal dilation to bradykinin were excluded
from analysis.
Statistical analyses were performed using SigmaStat
software (Systat Software, Inc., San Jose, CA) and PASW
Statistics 18 software (SPSS, Inc., Chicago, IL). Data are
expressed as mean ± SEM. Group comparisons for
in vivo and microvessel data were analyzed using 2-Way
ANOVA with the Holm-Sidak post hoc test applied for
significant interactions. The Kruskal Wallis ANOVA was
used when data were not normally distributed. Individ-
ual androgen response comparisons between intacts and
castrates were analyzed using t-tests and the Mann–
Whitney Rank Sum test when data were not normally
distributed. Individual androgen response comparisons
to baseline for intacts and castrates were analyzed using
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for PCR and immunohistochemistry data were ana-
lyzed using t-tests or the Mann–Whitney Rank Sum
test. A P value≤ 0.05 was deemed significant.
Results
Flow studies in anesthetized swine
Baseline coronary blood flow (CBF) measured at the be-
ginning of the flow studies prior to drug infusion was
similar between intact and castrated males (33.46 ± 5.1
and 35.63 ± 4.94 mL/min, respectively; Table 1). During
the androgen infusions, the intact males demonstrated
a significant increase in CBF from baseline for the 1,
10, and 100 nM doses of testosterone (5.31 ± 1.90,
8.72 ± 2.90, and 6.72 ± 2.65%, respectively), the 1, 10, and
100 nM doses of 5α-dihydrotestosterone (12.17 ± 5.62,
3.51 ± 1.45, 6.94 ± 2.44%, respectively), and the 10 nM
dose of epitestosterone (8.09 ± 3.71%). In contrast to the
intacts, the castrated males demonstrated a significant
increase in CBF only after the 100 nM dose of testoster-
one (2.86 ± 1.16%). The increases in blood flow during
the 10 nM testosterone and 1 nM 5α-dihydrotestoster-
one infusions in the intacts were significantly greater
than the responses present in the castrated malesTable 1 In Vivo Hemodynamic Responses
Intacts Castrates
Baseline CBF (mL/min) 33.46 ± 5.10 35.63 ± 4.94
% Δ Flow
T 1 nM 5.31 ± 1.90 * −0.84 ± 2.43
T 10 nM 8.72 ± 2.90 *† 2.57 ± 1.62
T 100 nM 6.72 ± 2.65 * 2.86 ± 1.16 *
DHT 1 nM 12.17 ± 5.62 *† −1.64 ± 3.29
DHT 10 nM 3.51 ± 1.45 * 1.54 ± 2.14
DHT 100 nM 6.94 ± 2.44 * 2.08 ± 1.20
EpiT 1 nM 7.85 ± 4.07 4.38 ± 2.63
EpiT 10 nM 8.09 ± 3.71 * 4.80 ± 2.44
EpiT 100 nM 3.59 ± 1.78 2.60 ± 3.56
Baseline MAP (mmHg) 64.93 ± 8.99 76.33 ± 8.85
% Δ Pressure
T 1 nM −0.13 ± 0.47 −0.23 ± 0.38
T 10 nM −0.51 ± 0.38 −1.92 ± 0.53 *
T 100 nM −0.4 ± 0.51 −1.64 ± 0.49 *
DHT 1 nM −0.78 ± 0.52 −0.71 ± 0.63
DHT 10 nM −0.7 ± 0.32 −1.12 ± 0.74
DHT 100 nM −0.33 ± 0.26 −0.63 ± 0.42
EpiT 1 nM −0.37 ± 0.53 −0.95 ± 0.52
EpiT 10 nM −0.38 ± 0.33 −0.63 ± 0.33
EpiT 100 nM −0.64 ± 0.40 −0.93 ± 0.42 *
Coronary blood flow (CBF) and mean arterial pressure (MAP) responses to
infusions of Testosterone (T), 5α-Dihydrotestosterone (DHT), and
Epitestosterone (EpiT). *p< 0.05 vs. baseline, †p< 0.05 vs. castrates. n = 7-8 for
intacts, n = 5-9 for castrates. Values are mean ± SEM.(8.72 ± 2.90 vs. 2.57 ± 1.62%, and 12.17 ± 5.62 vs.
-1.64 ± 3.29%, respectively).
Baseline mean arterial pressure (MAP) measured at
the start of the flow studies was not significantly differ-
ent between the intact and castrated males (64.93 ± 8.99
and 76.33 ± 8.85 mmHg, respectively; Table 1). During
the androgen infusions, there was a small but significant
drop in MAP from baseline in the castrates for the 10
and 100 nM doses of testosterone (−1.92 ± 0.53 and
−1.64 ± 0.49%, respectively) and the 100 nM dose of epi-
testosterone (−0.93± 0.42%). MAP did not vary signifi-
cantly from baseline during the intact androgen infusions.
Coronary conductance was significantly increased
from baseline in the intacts for the 1, 10, and 100 nM
doses of testosterone (5.29 ± 1.70, 9.07 ± 3.39, and
7.14 ± 2.96%, respectively), the 1, 10, and 100 nM doses
of 5α-dihydrotestosterone (12.76 ± 5.90, 4.40 ± 1.38, and
7.37 ± 2.53%, respectively), and the 10 and 100 nM doses
of epitestosterone (8.57 ± 3.86 and 4.32 ± 1.74%, respect-
ively; Figure 1). Conversely, conductance was only
increased in the castrated males from baseline during
the 100 nM dose of testosterone (4.56 ± 1.33%).Flow studies in conscious swine
The intact animals demonstrated increased coronary
conductance during the 1 and 10 nM testosterone infu-
sions (20.03 ± 6.45 vs. 0.61%, and 13.71 ± 4.04 vs. 5.89%,
respectively), as well as the 1 and 10 nM epitestosterone
infusions (24.73 ± 7.96 vs. 2.52%, and 19.18 ± 15.97 vs.
-4.25%, respectively) compared to the castrated animals
(Figure 2). Thus, these responses in conscious swine
were similar to that observed in anesthetized animals.
However, due to the small sample sizes, a statistical anal-
ysis was not performed.Microvessel studies
Coronary microvessels from intact males demonstrated
a significant dilation from baseline to 10 and 100 nM
testosterone (13.86 ± 4.39 and 26.63 ± 5.74% maximal
dilation, respectively); 1, 10, and 100 nM concentrations
of 5α-dihydrotestosterone (9.00 ± 4.29, 16.56 ± 6.15, and
20.76 ± 6.08% maximal dilation, respectively); and 1, 10,
and 100 nM epitestosterone (6.19± 1.88, 13.73± 3.64, and
23.07± 6.67% maximal dilation, respectively; Figure 3).
Arterioles from castrated males showed similar dila-
tion responses to 1, 10, and 100 nM testosterone
(11.54±3.30, 17.63±4.23, and 23.29±4.87% maximal dila-
tion, respectively) and 1 and 100 nM 5α-dihydrotestosterone
(8.37±2.52 and 15.44±5.25% maximal dilation, respect-
ively). However arterioles from castrated males did not
show a significant dilation compared to baseline for epites-
tosterone (1.40±1.24, 5.19±3.09, 8.93±6.50% maximal
dilation).
Figure 1 In vivo effects of androgen on the coronary circulation in anesthetized swine. Percent change in left anterior descending
coronary conductance from baseline for intact and castrated males during infusions of (a) Testosterone, (b) 5α-Dihydrotestosterone and
(c) Epitestosterone (n = 7-8 for intacts, n = 5-9 for castrates). Values are mean± SEM. *p< 0.05 vs. baseline. The testosterone and 5α-
dihydrotestosterone infusions demonstrate a main effect of castration on coronary conductance.
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Intact animals demonstrated a significant increase in
coronary conductance from baseline during the epites-
tosterone infusion (5.05 ± 2.06%) that was not dimin-
ished by flutamide (Figure 4). Dihydrotestosterone
infusion also produced an ~7% increase in coronary con-
ductance in the absence of flutamide, while in the pres-
ence of flutamide dihydrotestosterone did not increase
conductance over baseline (0.47 ± 1.90).qRT-PCR analysis
In the LAD, the castrated males showed a trend for
reduced androgen receptor mRNA expression though the
difference was not significantly different between the
intacts and castrates (1.00±0.25 and 0.62±0.06, respect-
ively) (Figure 5A). In coronary resistance vessels, androgen
receptor mRNA levels were similar in intact and castrated
males (1.00±0.27 and 1.15 ±0.35, respectively) (Figure 5B).Immunohistochemistry
Sections from the LAD demonstrated androgen receptor
expression in both the endothelium and in smoothTestosterone



































Figure 2 In vivo effects of androgen on the coronary circulation in co
conductance from baseline for intact, castrated, and testosterone replaced
and (c) Epitestosterone (n = 2 for intact, n = 1 for castrates, n = 1-2 for horm
epitestosterone infusions demonstrate a trend for increased coronary cond
replaced males.muscle cells of the media. Staining was most intense
in the cell nuclei, with cytoplasmic staining also visible
(Figure 6A). Microvessels evaluated for androgen recep-
tor expression also demonstrated staining in the endothe-
lium and surrounding smooth muscle cells (Figure 6B).
The surrounding adventitia and myocardium demon-
strated predominantly nuclear androgen receptor expres-
sion. The amount of staining in the intima and media
was quantified as a percent of the total vessel area. In
the LAD, androgen receptor expression was not statisti-
cally different between the intact and castrated males
(62.37± 5.64 and 51.69 ± 4.56%, respectively) (Figure 6C).
In ventricular microvessels, androgen receptor expression
was similar in both the intact and castrated males
(62.72± 4.07 and 59.04± 4.83%, respectively)(Figure 6D).Discussion
The current study is the first to demonstrate acute
in vivo vascular responses to exogenous androgen
administration are dependent upon endogenous andro-
gen status. The increased coronary conductance in the






















nscious swine. Percent change in left anterior descending coronary
males during infusions of (a) Testosterone, (b) 5α-Dihydrotestosterone
one replaced). Values are mean± SEM. The testosterone and
uctance in the intact males compared to the castrated and hormone
Figure 3 In vitro effects of androgen on coronary microvessel diameter. Percent maximal dilation of coronary resistance vessels from intact
and castrated males exposed to physiologic concentrations of (a) Testosterone, (b) 5α-Dihydrotestosterone, and (c) Epitestosterone (n = 12 for
intacts, n = 9 for castrates). Values are mean± SEM. *p< 0.05 vs. baseline. The epitestosterone exposures demonstrate a main effect of castration
on coronary microvessel diameter.
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sion. Furthermore, these experiments provide the first
evidence for a physiologic effect of the androgen, epites-
tosterone, on the vasculature.
In the present study, nanomolar concentrations of an-
drogen produced statistically significant increases in cor-
onary conductance and microvessel diameter.
Circulating testosterone levels in human males range
from 11–44 nM [13], though the majority of in vitro
studies have used supraphysiologic doses in the micro-
molar range to induce vascular dilation responses
[15,16,18,33,34]. In contrast to the majority of in vitro
data, several in vivo studies evaluating the effects of
androgen on coronary blood flow have demonstrated
significant increases in flow following the infusion of
physiologic concentrations of androgen [13,14,17]. The
magnitude of the androgen induced flow response, how-
ever, has varied in previous studies. Webb et al. used
1–100 nM doses of testosterone in men with coronaryFigure 4 In vivo effects of flutamide on coronary vascular
responses to androgen. Percent change in coronary conductance
from baseline for intact males during 10 nM infusions of
Epitestosterone (EpiT) and 5α-Dihydrotestosterone (DHT) alone and
in the presence of 10 μM flutamide (n = 6). Values are mean± SEM.
*p< 0.05, # <0.06 vs. baseline.artery disease to induce a 12-17% increase in coronary
blood flow [13], while Chou and colleagues demon-
strated a striking 78-86% increase in coronary blood
flow following the administration of 1 μM testosterone
in anesthetized dogs [14]. In the present study coron-
ary blood flow increased ~5-8% during the testosterone
infusions in the anesthetized intact males. The large
variation in coronary blood flow responses in the
current literature may be related to differences in the
methods used to measure or calculate hemodynamic
variables, effects of baseline flow on actual concentra-
tions of androgen achieved in the coronary circulation,
or perhaps species differences in response to exogen-
ous androgen. A similar study in anesthetized pigs
demonstrated increases in coronary blood flow consistent
with our data following a 1 μg/L infusion of testosterone
[17]. However in contrast to the present study, prepubertal
male and female pigs were used for all flow evaluations.
This study is the first to directly compare flow
responses between intact and castrated males. During
the in vivo experiments in the anesthetized pigs, a main
effect of castration was observed for the testosterone
and 5α-dihydrotestosterone infusions. Conversely, the
microvessel studies did not demonstrate statistically
significant differences between the dilation responses
of intact and castrated subjects to testosterone and
5α-dihydrotestosterone. The reasons for the inconsist-
encies between the flow and microvessel data may be
related to several factors. In the in vivo studies, andro-
gen was infused directly into the LAD and therefore had
preferential access to the endothelium. However in the
microvessel studies, the androgen was administered dir-
ectly into the bath and as a result contacted the smooth
muscle cells of the media first. Because of the different
cell types involved and possible differences in drug dif-
fusion through the intima and media, the different ex-
perimental conditions create the potential for variable
activation of dilator pathways. Another reason for the
dilation differences noted in the microvessel studies may
Figure 5 Androgen receptor gene expression in intact and castrated males. Quantitative RT-PCR analysis of androgen receptor (AR) mRNA
levels in intact and castrated males in the (a) left anterior descending coronary artery (LAD) (n = 9 for intacts, n = 7 for castrates) and (b) left
ventricular microvessels (MV) (n = 10 for intacts, n = 8 for castrates). AR gene expression was normalized to GAPDH gene expression using the 2 -ΔΔCT
method. Values are mean±SEM.
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the complex, integrated signal conditions present in vivo.
In the microvessel studies, the effects of androgen on
spontaneous tone were evaluated. Conversely, in the
in vivo studies, numerous other hormones, vasoactive
and hemodynamic factors contribute to basal tone [35],
and potentially contributed to the differential response be-
tween the intact and castrated males. Furthermore,
because the in vivo studies were performed several hours
prior to the microvessel studies, it is possible that andro-
gen administration in vivo activated genomic actions in
the vasculature that persisted in the in vitro studies. These
observations indicate that in vitro studies are useful toFigure 6 Androgen receptor immunohistochemistry in intact and cas
localization in the (a) LAD and (b) coronary microvessel (MV). Insets: Repres
staining in the (c) LAD (n = 7 for intacts, n = 8 for castrates) and (d) left venconfirm the dilatory action of androgen on the coronary
resistance vessels, however in order to determine the
mechanism and clinical relevance of androgen induced
dilation, in vivo studies are critical.
In the current study the role of the androgen receptor
in the mechanism of androgen induced vascular dilation
was examined. Previous research has evaluated the clas-
sical androgen receptor for its potential involvement
in vascular dilation. The classic androgen receptor is a
nuclear receptor that, upon testosterone or dihydrotes-
tosterone binding, initiates protein synthesis. This gen-
omic pathway; however, typically requires several hours
for completion, with some effects detectable at atrated males. Representative photomicrographs demonstrating AR
entative non-immune controls. Quantitative histological analysis of AR
tricular MV (n = 6 for intacts, n = 5 for castrates). Values are mean± SEM.
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testosterone induced dilation occurs acutely, only several
minutes after administration of the hormone, the pre-
dominant view is that testosterone must also be involved
in a non-genomic pathway. Research has recently identi-
fied androgen receptor mediated non-genomic pathways
in addition to the classic nuclear androgen receptor
pathway. The non-genomic pathways induce rapid
responses and involve androgen receptor interactions in
the cytoplasm or at the plasma membrane of the cell,
leading to the activation of various protein kinases [36].
A recent paper by Yu and colleagues demonstrated the
ability of testosterone and 5α-dihydrotestosterone to
upregulate the phosphorylation of eNOS in human aor-
tic endothelial cells through androgen receptor mediated
activation of the phosphoinositide-3 kinase/Akt pathway.
Specifically, the androgen receptor interacted directly
with the p85α subunit of PI3-kinase. The upregulation
of nitric oxide production in this study was inhibited
when the androgen receptor antagonist nilutamide was
administered [28]. In the current study, a group of
anesthetized, intact male pigs received in vivo intracor-
onary infusions of 5α-dihydrotestosterone and epitestos-
terone in the presence of flutamide. The dilation
induced by epitestosterone was not attenuated in the
presence of flutamide; however, the response to
5α-dihydrotestosterone, an androgen with a high affinity
for the androgen receptor, was diminished by flutamide.
As a caveat, 10 uM flutamide has been used previously in
in vitro work [16,18], but its efficacy in vivo has not been
evaluated extensively. It is also possible that androgen
causes vascular dilation through multiple pathways,
including the direct blockage of L-type Ca2+ channels or
activation of large-conductance calcium-sensitive K+
channels [37]. As a result, only part of the dilation
response may be androgen receptor mediated and suscep-
tible to flutamide antagonism. Thus, the results from
the present study indicate that the dilation response to
5α-dihydrotestosterone was largely mediated by andro-
gen receptor activation, while the epitestosterone dila-
tion response did not appear to involve activation of
the androgen receptor.
Due to the conductance differences between the intact
and castrated males in the present study and the poten-
tial involvement of the androgen receptor in these
responses, androgen receptor expression was evaluated
in the conductance and resistance coronary vessels. Pre-
vious work has demonstrated an up-regulation of andro-
gen receptor mRNA and protein in vascular smooth
muscle cells exposed to varying concentrations of testos-
terone [38] and reduced androgen receptor staining in
castrated males compared to the intact males [32].
We therefore hypothesized that a reduction in circulat-
ing testosterone would induce a down regulation ofandrogen receptor expression and may be associated
with the different conductance responses observed in
the intact and castrated males. However in the present
study androgen receptor mRNA levels and protein in
the LAD and coronary microvessels were not different
between the intacts and castrates. The current literature
regarding post castration androgen receptor expression
is indeed quite variable and tissue specific. Prostate epi-
thelial and stromal cells of castrated male guinea pigs
demonstrated a lack of androgen receptor staining four
days post castration, however brain nuclei staining was
unchanged following castration [39]. In rat skeletal
muscle, castration reduced androgen receptor expression
in the bulbocavernosus muscle, but had no effect on the
levator ani muscle [40]; while in bovine skeletal muscle
castration was associated with an increase in androgen
receptor mRNA in the semitendinosus and triceps bra-
chii but not the splenius [41]. Interestingly, in castrated
human males, androgen receptor expression was signifi-
cantly increased in leukocytes compared to age matched
controls [42]. In light of these studies, androgen receptor
expression in the vasculature following castration may
also be location and cell type dependent. However with
regard to the current study, because androgen receptor
expression was quantified in both the large conduit
vessels and resistance coronary microvessels, it may be
concluded that differences in conductance responses
between intact and castrated males during exogenous
androgen administration were not due to differences in
androgen receptor protein expression.
Importantly, the current study is the first to demon-
strate the vascular effects of the epimer epitestosterone.
Described as a weak anti-androgen, epitestosterone has
been thought to be largely biologically inactive. However,
coronary conductance was increased in the anesthetized,
intact males during the 10 and 100 nM epitestosterone
infusions, and in the microvessel experiments, vascular
dilation was observed for all doses of epitestosterone.
Furthermore, the magnitude of the vasomotor responses
was similar to both testosterone and 5α-dihydrotestosterone.
Dilation induced by epitestosterone was not attenuated by
the presence of flutamide, suggesting that epitestosterone
does not function through the androgen receptor to induce
vascular dilation. The present study provides the first
evidence of a physiologic role for epitestosterone in coron-
ary regulation, and indicates further research is necessary
to evaluate its physiological relevance and therapeutic
potential.
Several limitations to the current study should be con-
sidered. The mean age of the intact males was significantly
higher than the castrated males (20.83±4.79 months vs.
3.8 ± 0.39 months). However, post hoc analysis demon-
strated the in vivo vascular responses in younger intact
males (5.33±0.33 months, n =3) were not different from
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this concern. The small group size of the conscious ani-
mal experiments and the potential effect of anesthesia on
the coronary responses in the majority of the flow stud-
ies are also acknowledged. However, the conscious,
chronically instrumented pigs demonstrated a similar
trend for increased coronary conductance during acute
androgen administration in the intact compared to the
castrated males. With regard to the immunohistochemis-
try data, while it was demonstrated that differences did
not exist in androgen receptor protein expression be-
tween the intacts and castrates, the functionality of these
receptors is unknown. As a result, it is possible that
intracellular signaling pathways are different between the
two groups and could contribute to differences in vascu-
lar reactivity to androgen. Finally, the serum testosterone
levels from all of the pigs used in the flow studies and
microvessel studies were not measured, and therefore
exact differences in androgen status between the two
study groups are unknown. However, historical data from
our lab found intact males to have testosterone levels in
the range of 200 ng/dL, while castration reduces circulat-
ing testosterone by >90% [8].
In conclusion, the present study is the first to examine
the role of endogenous hormone status on acute vaso-
motor responses to physiologic concentrations of testos-
terone, 5α-dihydrotestosterone and epitestosterone. The
data demonstrate significantly increased conductance
responses in the intact males compared to the castrates,
but this response was not associated with differences in
androgen receptor expression as assessed by immuno-
histochemistry between the two groups. Additionally,
the intacts demonstrated a significant dilation response
to the epimer epitestosterone, which provides the first
evidence for a physiologic role of this androgen on the
coronary vasculature. Results from this study suggest
that the efficacy of androgen therapy in hypogonadal
men may be dependent on endogenous testosterone
levels, and further research is necessary to evaluate the
dilation pathways involved in acute vascular responses
to androgen.
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